Pliant Therapeutics shares surge 13.64% premarket after interim trial shows tumor responses with PLN-101095 in ICI-refractory cancers.

Pliant Therapeutics surged 13.64% in premarket trading following the release of interim Phase 1 data showing PLN-101095 combined with pembrolizumab generated four responses (one confirmed complete response, two confirmed partial responses, one unconfirmed partial response) in 10 ICI-refractory tumor patients. The trial, reported on December 4, 2025, highlighted durable responses with a median 15-month treatment duration, 60% stable disease or tumor reduction, and a strong biomarker correlation (4–13-fold increases in plasma IFN-γ in responders). The drug was well tolerated, with only two treatment discontinuations, and the company announced plans to advance to a Phase 1b expansion trial in 2026. A robust cash runway through 2028 further reinforced optimism, aligning with the stock’s sharp premarket rise.